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ABSTRACT
Background. Identifying predictors of treatment toxicity and
overall survival (OS) is important for selecting patients who will
benefit from chemotherapy. In younger patients with cancer,
muscle mass and radiodensity are associated with treatment
toxicity and OS. In this study, we investigated whether muscle
mass, radiodensity, and strength were associated with treat-
ment toxicity and OS in patients with advanced cancer aged 60
years or older.
Materials and Methods. Before starting palliative chemother-
apy, muscle mass and radiodensity were assessed using com-
puted tomography scans and muscle strength was assessed
using a hydraulic hand grip dynamometer. Treatment toxicity
was defined as any toxicity resulting in dose reduction and/or
discontinuation of treatment. Multiple logistic and Cox regres-
sion analyses were performed to study potential associations of
muscle mass, radiodensity, and strength with treatment toxicity
and OS, respectively.
Results. The participants were 103 patients, with a mean age of
70 years, with advanced colorectal, prostate, or breast cancer.
Muscle parameters were not significantly associated with treat-
ment toxicity. Higher muscle strength was associated with longer
OS (hazard ratio 1.03; 95% confidence interval 1.00–1.05). Muscle
mass and radiodensity were not significantly associatedwith OS.
Conclusion. Higher muscle strength at the start of palliative
chemotherapy is associated with significantly better OS in older
patients with advanced cancer. None of the investigated muscle
parameters were related to treatment toxicity. Future studies
are needed to evaluate whether muscle strength can be used
for treatment decisions in older patients with advanced cancer.
The Oncologist 2018; 23:580–585
Implications for Practice: This study in older patients with advanced cancer showed that adequate muscle strength is associated
with longer overall survival. The results of this study imply that muscle strength might be helpful in estimating survival and
therefore in identifying older patients who will benefit from anticancer treatment.
INTRODUCTION
Systemic treatment of older patients with cancer is challeng-
ing because of the heterogeneous conditions and comorbid-
ity of this population and a lack of knowledge caused by
underrepresentation of this group of patients in clinical stud-
ies [1]. The high prevalence of treatment toxicity and the
higher mortality rate caused by higher disease-specific mor-
tality and competing comorbidity further complicate
decision-making in this population [2–4]. Knowledge of pre-
dictors for treatment toxicity and survival can contribute to
the identification of patients who will benefit from
treatment with chemotherapy. Low muscle mass and
impaired muscle radiodensity have been found in adult
patients with cancer and in healthy older adults [5, 6]. In
adults with cancer, low muscle mass and increased fat infil-
tration of the muscle, reflecting lower muscle radiodensity
(i.e., low muscle attenuation), have been observed in 15%–
55% of patients and were found to be predictive for treat-
ment toxicity and survival [5, 7–11]. Decrease in muscle mass
and muscle radiodensity is associated with aging [6, 12].
Depending on the definition, the prevalence of low muscle
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mass in older adults is up to 50% [13, 14]. Muscle radioden-
sity is generally lower in older than in younger adults [6].
Because of the observed decrease in muscle mass and mus-
cle radiodensity, both in patients with cancer and in patients at
older age, it is likely that the combination of these two factors
(cancer and old age) affects muscle parameters even more
severely. Several studies have investigated muscle mass in
patients with advanced cancer and reported age-related
differences, with conflicting results regarding prevalence of low
muscle mass [5, 8, 10, 15, 16]. However, age-related differences
in prevalence of low muscle radiodensity have not been
reported in patients with advanced cancer.
Next to muscle mass and muscle radiodensity, muscle
strength is a third important determinant of muscle depletion
[17]. In the general population, muscle strength contributes to
the identification of both the most fit and the most vulnerable
older patients [18–20]. Therefore, muscle strength may be a
predictor of treatment toxicity and survival in older patients
with cancer. In addition, muscle strength has been shown to be
a predictor of poor clinical outcome in younger patients with
advanced cancer [21].
In this study, we prospectively studied the association of
muscle mass, muscle radiodensity, and muscle strength with
both treatment toxicity and overall survival (OS) in a cohort of
older patients with advanced cancer.
MATERIALS AND METHODS
The present study was conducted as part of a large prospective
study on nutritional status and muscle measures in patients
with advanced cancer at the Vrije Universiteit Medical Center
(VUmc), Amsterdam, The Netherlands. A first analysis of these
data was published in 2014 [22], and changes in muscle mass
during treatment for metastatic colorectal cancer (CRC) were
reported in 2016 [23].
The research protocol was approved by the medical ethics
committee of the VUmc, and the study was performed accord-
ing to the 1964 Declaration of Helsinki. Written informed
consent was obtained from all patients prior to participation.
Patients
In the large prospective study, eligible patients had advanced
CRC or breast, prostate, or lung cancer and were scheduled to
receive the first cycle of palliative chemotherapy or the first
cycle of a new line of chemotherapy. Patients were excluded
who had been treated with anticancer therapy within the last
30 days, who had ascites or serious pitting edema, or who
were not able or willing to provide informed consent. Patients
were recruited from the outpatient clinic and medical ward of
the VUmc between October 2011 and July 2014.
For the current analysis we selected patients aged 60 years
and older with CRC or breast or prostate cancer who had an
evaluable computed tomography (CT) scan of the abdomen
available within 40 days of the start of treatment. Because of
absence of CT scans of the abdomen in the majority of patients
with lung cancer, this group of patients was not included in this
analysis.
Anthropometry
Body weight and height were assessed before the start of
chemotherapy. Height was measured to the nearest cm using a
stadiometer while the patient was standing barefoot. Weight
was measured within 0.2 kg on a calibrated scale (seca type
888, seca GmbH, Hamburg, Germany). Body mass index (BMI)
was calculated as the ratio of body weight to height squared
(kg/m2).
Muscle Measures
Muscle Mass and Muscle Radiodensity
All CT scans were obtained for clinical purposes. Muscle mass
and muscle radiodensity were measured by analysis of elec-
tronically stored CT images. A certified investigator analyzed
images using commercially available software (sliceOmatic
version 5.0; TomoVision, Magog, Canada) on a single-slice
transverse CT image located at a standard vertebral landmark,
L3 [24]. The software was used to specify the different tissues
based on their anatomical features and pre-established thresh-
olds of Hounsfield units (HU). For skeletal muscle the range of
HU is 229 to 1150 HU, and for intermuscular adipose tissue,
2190 to 230 HU [25].
Lumbar skeletal muscle measured at L3 is related to whole
body muscle mass and is the sum of the paraspinal muscles
(quadratus lumborum, erector spinae), psoas muscles, transver-
sus abdominis, internal and external oblique, and rectus
abdominis [24]. The software computed the surface area of
lumbar skeletal muscle (e.g., cm2), and this value of muscle
mass was normalized for stature using the lumbar skeletal
muscle index (SMI, cm2/m2) [24]. Muscle radiodensity, also
described as muscle attenuation, was measured using the mus-
cle radiation attenuation rate (in HU).
Low muscle mass (low SMI) and low muscle radiodensity
were defined according to the sex- and BMI-specific threshold
values associated with low survival by Martin et al [7].
Muscle Strength
Hand grip strength is a valid indicator of general muscle
strength and, being a bedside method, it is the most frequently
used clinical tool to determine muscle strength [26]. Hand grip
strength was measured using a hydraulic hand dynamometer
(Baseline, Fabrication Enterprises, White Plains, NY). Patients
performed the test while sitting with the shoulder adducted
and neutrally rotated, elbow flexed at 90 degrees, and forearm
and wrist in neutral position. Patients were instructed to per-
form one practice contraction. Subsequently, each patient per-
formed two maximal isometric contractions with the left hand
and two with the right hand. Maximal hand grip strength was
defined as the maximum value of four contractions and was
recorded to the nearest 0.5 kg. Low muscle strength was deter-
mined by sex-specific cutoff values for maximal hand grip
strength (<30.3 kg for men and<19.3 kg for women) [27].
Treatment Toxicity
Treatment toxicity was obtained from medical records and
consisted of any toxicity leading to dose reduction or discontin-
uation of chemotherapy, such as (febrile) neutropenia, neuro-
toxicity, gastrointestinal symptoms, and fatigue. Treatment
modifications due to other causes, such as progressive disease
or vacation, were not taken into account. Treatment toxicity
was dichotomized into present or absent. Furthermore, time
until treatment toxicity and up-front dose reductions were
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noted. Early treatment toxicity was defined as toxicity occurring
within 42 days (two cycles of treatment).
Survival
OS data were obtained at least 1 year after inclusion of the last
patient. The median length of follow-up was 436 days
(interquartile range 414). Patients who were still alive were
censored on the date of last consultation. Six-month OS was
calculated.
Covariates
Demographic and clinical data were retrieved from medical
records. Age, sex, cancer type, and World Health Organization
and Eastern Cooperative Oncology Group performance statuses
were recorded before the start of treatment with chemother-
apy. Comorbidity was assessed with the Charlson Comorbidity
Index [31]. A score of 2 indicates severe comorbidity. Poly-
pharmacy was defined as the use of five or more medications.
Treatment line was defined as consecutive chemotherapy line
and dichotomized as first-line or at least second-line.
Statistical Analysis
All analyses were performed using SPSS for Windows, version
22.0 (IBM, Armonk, NY). Descriptive statistics were used to
describe the basic features of the data. Continuous data were
tested for normal distribution and presented as mean and stand-
ard deviation (SD). Pearson’s chi-squared test was applied to
investigate statistically significant differences between groups
when appropriate. Pearson correlation was used to investigate
the correlation between SMI and hand grip strength. To investi-
gate whether there was an association between muscle meas-
ures and treatment toxicity, univariable and multiple logistic
regression analyses were applied. For this analysis, muscle meas-
ures were investigated as continuous variables. Odds ratios and
corresponding 95% confidence intervals (CIs) were reported.
To investigate median OS per tumor type, the Kaplan-Meier
method was used.
Associations between muscle measures (continuous varia-
bles) and OS were investigated with univariable and multivari-
able Cox regression analyses. Hazard ratios and corresponding
95% CIs were reported.
To investigate the clinical value of muscle measures that
were significantly associated with OS, we also studied the asso-
ciation of low versus normal muscle measures based on age-
and gender-based cutoff values, with OS using Cox regression
analysis. Furthermore, the discriminative value of investigated
cutoff values was examined by calculating sensitivity and
specificity, as well as the area under the receiver operating
characteristics (ROC) curve, with 0.70–0.80 representing fair
and 0.80–1.00 representing good discrimination [28].
In the multivariable logistic and Cox regression analyses, we
adjusted only for relevant confounders (defined as change of
the regression coefficient of at least 10%) because of the sam-
ple size. Potential confounders included age, sex, comorbidity,
cancer type, and treatment line. In the final analyses, age and
comorbidity were not relevant and therefore not adjusted for.
A p value of.05 was considered significant for all analyses.
RESULTS
Of 364 patients included in the original study, 103 patients
were eligible for the present analysis based on age, cancer
type, and available CT scan. The mean age of patients was 70.0
years (SD 6.6), and 66% were men (Table 1). Approximately half
of patients were diagnosed with CRC (52%), and 75% received
first-line cytotoxic treatment. Ten percent of patients had
severe comorbidities, and polypharmacy was present in 39%.
The mean SMI was 46.7 cm2/m2 (SD 7.5) in men and
38.4 cm2/m2 (SD 6.3) in women. Mean radiodensity was 31.9
HU (SD 8.3) in men and 30.5 HU (8.8) in women. Mean hand
grip strength was 39.8 kg (SD 10.8) in men and 25.5 kg in
women (SD 7.0). Table 2 shows the mean muscle measures for
all patients and for each cancer type separately. Low muscle
mass was present in 66% of patients, low muscle radiodensity
in 88%, and low muscle strength in 21%. There was a
Table 1. Patient characteristics (n 5 103)
Characteristics n (%)
Age, yearsa 70.0 (6.6)




















Body mass index, kg/m2
<20 kg/m2 4 (4)
20–24.9 kg/m2 35 (34)
25–29.9 kg/m2 53 (52)
30 kg/m2 11 (11)
Skeletal muscle index, cm2/m2a
Men 46.7 (7.5)
Women 38.4 (6.3)
Muscle attenuation, HUa 31.5 (8.4)




bPolypharmacy is defined as five or more different types of medication.
Abbreviations: HU, Hounsfield units; WHO,World Health Organization.
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correlation between SMI and hand grip strength only in male
patients (male p 5 .003; female p 5 .137)
Treatment Toxicity
Treatment toxicity occurred in 46 patients (46%), resulting in
dose reduction in 27 patients and discontinuation of treatment
in 19 patients. In total, 19 patients (18%) started treatment
with a reduced dose up front. The prevalence of treatment tox-
icity did not differ significantly between patients with and with-
out baseline dose reductions (58% vs. 42%; p 5 .199.) Thirty-
seven percent of treatment toxicities were early treatment tox-
icities (within 42 days of treatment).
After adjusting for sex, cancer type, and up-front dose
reductions, we found no significant association of SMI (OR
1.04, 95% CI 0.97–1.11), muscle attenuation (OR 1.03, 95% CI
0.98–1.09), or muscle strength (OR 1.01, 95% CI 0.96–1.06)
with treatment toxicity (Table 3). Adjusting for or limiting treat-
ment toxicity to early treatment toxicity (within 42 days of
treatment) did not change this.
Overall Survival
Median OS did not differ significantly per tumor type; it was
14.8 months (95% CI 10.56–19.08) for patients with CRC, 15.0
months (95% CI 4.46–25.50) for patients with breast cancer,
and 17.7 months (95% CI 8.17–27.31) for patients with prostate
cancer (p 5 .986).
After adjusting for sex, cancer type, and treatment line,
higher muscle strength was significantly associated with longer
survival (hazard ratio [HR] 1.03, 95% CI 1.00–1.05; Table 3).
No significant associations were found between survival and
muscle mass or muscle attenuation.
Furthermore, patients with normal muscle strength based
on cutoff values had significantly longer OS than patients with
low muscle strength (median OS 16.5 months vs. 10.1 months;
HR 1.75, 95% CI 1.02–3.00; Fig. 1) [23].
The sensitivity of low muscle strength in predicting
six-month OS was 40%, and specificity was 82%.The area under
the ROC curve was 0.61.
DISCUSSION
In this study, we evaluated whether muscle mass, muscle radio-
density, and muscle strength were predictive for treatment tox-
icity and survival in older patients treated with chemotherapy
for advanced cancer. Patients with higher muscle strength had
longer OS than patients with lower muscle strength. Muscle
measures and treatment toxicity were not associated with OS.
Table 2. Muscle measures
Muscle measures
All cancer types
(n 5 103): mean (SD)
CRC (n 5 54):
mean (SD)
Prostate (n 5 34):
mean (SD)
Breast (n 5 15):
mean (SD)
Male Female Male Female Male Female Male Female
Skeletal muscle index, cm2/m2 46.7 (7.5) 38.4 (6.3) 50.1 (6.5) 38.7 (6.2) 43.2 (6.9) — — 38.0 (6.7)
Radiodensity, 3 HU 31.9 (8.3) 30.5 (8.8) 34.3 (7.9) 32.9 (8.3) 29.6 (8.1) — — 27.4 (8.6)
Hand grip strength, kg 39.8 (10.8) 25.5 (7.0) 41.6 (11.5) 26.3 (7.6) 38.0 (9.9) — — 24.4 (6.2)
Abbreviations: —, no data; CRC, colorectal cancer; HU, Hounsfield units; SD, standard deviation.
Table 3. Associations between muscle measures and treatment toxicity and overall survival (n 5 103)
Muscle measures
Treatment toxicity Overall survival
Unadjusted Adjusteda Unadjusted Adjustedb
OR 95% CI p value OR 95% CI p value HR 95% CI p value HR 95% CI p value
SMI, cm2/m2 1.01 0.97–1.06 .57 1.04 0.97–1.11 .29 1.03 1.00–1.06 .06 1.04 1.00–1.08 .08
Muscle quality, HU 1.01 0.96–1.06 .65 1.03 0.98–1.09 .25 1.03 1.00–1.06 .03 1.03 1.00–1.06 .07
Hand grip strength, kg 1.02 0.99–1.05 .29 1.01 0.96–1.06 .70 1.02 1.00–1.04 .03 1.03 1.00–1.05 .04
aAdjusted for sex, cancer type, baseline dose reduction.
bAdjusted for sex, cancer type, treatment line.
Abbreviations: CI, confidence interval; HR, hazard ratio; HU, Hounsfield units; OR, odds ratio; SMI, skeletal muscle index (muscle mass).
Figure 1. Kaplan-Meier curve for the association of low hand grip
strength, defined as <30.3 kg for men and <19.3 kg for women,
and overall survival.
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The significant association between muscle strength and OS
supports findings from a previous study in patients with
advanced non-small cell lung and gastrointestinal cancer aged
18 years and older [21]. Muscle strength was also associated
with OS in healthy older adults [19]. This implies that muscle
strength, as a frailty marker, can potentially contribute to esti-
mating survival and may be used as a factor to select older
patients for anticancer treatment [29, 30]. However, although
this study showed that Lauretani’s cutoff values [27] for normal
muscle strength can be used to predict OS, their discriminative
value is low and may not be clinically useful [31]. This is mainly
due to low sensitivity and poor positive predictive value. The
low sensitivity found in this study might be caused by a rela-
tively high percentage of patients with up-front dose reduc-
tions who may have been fit to receive standard dosage [32].
In contrast with younger patients with advanced cancer [5,
7–11], muscle mass and muscle radiodensity were not signifi-
cantly associated with OS in our group of older patients with
advanced cancer. However, our finding that muscle strength is
more important than muscle mass in estimating OS in older
patients with advanced cancer supports the previous findings
of a cohort study among 2,295 healthy participants aged 70
years and older [18]. A possible explanation for the discrepancy
in findings between muscle mass and muscle radiodensity with
OS in older patients is the relatively low muscle mass and low
muscle radiodensity in our study compared with other studies
in patients with cancer [7, 10, 11]. When cutoff values were
used, the prevalence rates of low muscle mass and low muscle
radiodensity in our study population were higher than those
reported in younger patients with cancer [7]. This suggests that
in older patients with cancer, both aging and cancer may con-
tribute to loss of muscle mass and increase of fat accumulation
in muscle. Therefore, age-adjusted cutoff values for this group
of patients are needed. Furthermore, the finding of lower mus-
cle mass and lower muscle radiodensity in this population
raises the question of whether improving muscle strength
offers opportunities to improve OS, maintain functional inde-
pendence, or improve quality of life. For older people living in
the community, exercise-based rehabilitation interventions or a
resistance and aerobic exercise program have shown improve-
ments in physical function and reduction in falls [33, 34]. More-
over, in younger patients with breast cancer, it was shown that
a combined supervised resistance and aerobic exercise program
during adjuvant chemotherapy improved physical function and
muscle strength, and fewer dose adjustments were required
[35]. Future trials should investigate whether improving muscle
strength improves OS.
In contrast to findings from previous studies [5, 25], we found
no significant association between muscle mass, muscle radio-
density, and treatment toxicity. There are several possible explan-
ations for the lack of significant associations. First, we included
patients with three different cancer types andmultiple treatment
lines; therefore, treatment regimens were heterogeneous. A
previous study by Prado et al. and Barrett et al. [10, 36] included
a more homogeneous group of relatively young patients with
breast cancer (55 patients, mean age 55 years) or CRC (51
patients, median age 65 years) and one type of treatment. How-
ever, adjusting for cancer type did not change the association in
this study. Second, treatment toxicity in younger patients may be
due solely to pharmacokinetic effects caused by decreased
muscle mass [10], whereas in older patients, pharmacokinetic
effects are only partly responsible for causing treatment toxicity.
Treatment toxicity in older patients may be multifactorial.
Another possible cause is the aging of organ systems, such as the
peripheral nervous system or bone marrow [37].
Strengths of this study are the simultaneous assessments of
three important aspects of muscle (i.e., mass, radiodensity, and
strength), the specific focus on older patients with advanced
cancer, and the relatively large sample size. However, the inclu-
sion of three cancer types may have resulted in heterogeneous
treatment regimens. Although we did adjust for cancer type and
treatment line, there may be some residual confounding affect-
ing the association between muscle measures and treatment
toxicity. Probably most importantly, patients starting treatment
with chemotherapy were selected, which may have resulted in a
selected population with relatively high muscle strength.
CONCLUSION
In older patients treated for advanced CRC or breast or prostate
cancer, higher muscle strength is associated with longer OS.
Therefore, future studies should evaluate the clinical use of
muscle strength for judging whether or not a patient should
receive palliative treatment to further optimize treatment out-
come in this elderly population.
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